---
title: "SA Asks: What's the outlook for Big Pharma M&A?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295307267.md"
description: "Seeking Alpha analysts discuss the outlook for Big Pharma M&A, citing patent cliffs and revenue declines as key drivers. Bristol Myers Squibb's rumored merger talks with AstraZeneca highlight industry activity. Analysts predict increased focus on late-stage assets in oncology, neuroscience, and rare diseases, with potential targets including Krystal Biotech, TG Therapeutics, and Abivax to address loss of exclusivity."
datetime: "2026-08-08T19:44:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295307267.md)
  - [en](https://longbridge.com/en/news/295307267.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295307267.md)
generator: "portal-rs"
---

# SA Asks: What's the outlook for Big Pharma M&A?


### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)

## Related News & Research

- [Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi disposes of 6,249 common shares worth $403,700.93](https://longbridge.com/en/news/298642486.md)
- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)
- [Bristol Myers Swoons on Test Results](https://longbridge.com/en/news/298335284.md)
- [AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective](https://longbridge.com/en/news/298875452.md)
- [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**